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Anti-angiogenic strategies are emerging as an important tool for the treatment of cancer and inflammatory diseases. In the present investigation we isolated
several isoflavones from a tempeh (fermented soyabean) extract. The isolated isoflavones were identified as 5,7,40-trihydroxyisoflavone (genistein), 7,40-
dihydroxyisoflavone (daidzein), 6,7,40-trihydroxyisoflavone (factor 2), 7,8,40-trihydroxyisoflavone (7,8,40-TriOH) and 5,7,30,40-tetrahydroxyisoflavone
(orobol). The effects on angiogenesis of these isoflavones were evaluated in the chicken chorioallantoic membrane assay; their capacity to inhibit vascular
endothelial growth factor-induced endothelial cell proliferation and expression of the Ets 1 transcription factor, known to be implicated in the regulation of
new blood vessel formation, were also investigated. We found that all isoflavones inhibited angiogenesis, albeit with different potencies. Compared with
negative controls, which slightly inhibited in vivo angiogenesis by 6·30 %, genistein reduced angiogensis by 75·09 %, followed by orobol (67·96 %),
factor 2 (56·77 %), daidzein (48·98 %) and 7,8,40-TriOH (24·42 %). These compounds also inhibited endothelial cell proliferation, with orobol causing
the greatest inhibition at lower concentrations. The isoflavones also inhibited Ets 1 expression, providing some insight into the molecular mechanisms
of their action. Furthermore, the chemical structure of the different isoflavones suggests a structure–activity relationship. Our present findings suggest
that the new isoflavones might be added to the list of low molecular mass therapeutic agents for the inhibition of angiogenesis.
Soyabean: Tempeh: Isoflavones: Angiogenesis: Ets 1
Angiogenesis is a conserved process in vertebrates and is essential
for many physiological and pathological processes such as devel-
opment, wound healing, inflammation and tumour vascularization
(Folkman, 1995).
Continuing research efforts are directed towards understanding
the molecular mechanisms underlying new blood vessel for-
mation. Current models take into account an increasing number
of angiogenic and anti-angiogenic factors, including vascular
endothelial growth factor (VEGF), angiopoietin and ephrin
families and their receptors, as well as different transcription fac-
tors, including ets 1 (for reviews, see Folkman, 1995; Wernert,
1997; Pepper, 2000; Yancopoulos et al. 2000). The roles of
many of these factors have been determined by transgenic
approaches (Carmeliet & Collen, 2000).
Anti-angiogenic strategies aimed at blocking new blood vessel
formation under pathological conditions such as tumour vascular-
ization or rheumatoid arthritis (Wernert et al. 2002) are currently
emerging. These strategies include: (1) interference with angio-
genic ligands, their receptors and downstream signalling; (2)
up-regulation of endogenous inhibitors; (3) application of integrin
antagonists or inhibitors of matrix-degrading metalloproteinases
(Carmeliet & Jain, 2000; Feldman et al. 2000; Pfeifer et al.
2000; Pepper, 2001).
Successful blockade of angiogenesis has been demonstrated in
animal models when monoclonal antibodies or single-chain anti-
body fragments targeting VEGF (Brekken et al. 2000; Vitaliti
et al. 2000) or the integrin avb3 (Brooks et al. 1994) were used.
The integrin avb3 has also been targeted successfully with a
cyclic peptide antagonist of integrin avb3 (Brooks et al. 1994).
Other strategies that have been employed to inhibit angiogenesis
include intravascular injection of plasminogen-derived angiostatin
(Drixler et al. 2000), and adenoviral or lentiviral delivery of the
extracellular domain of VEGFR-1 (flt-1) (Shiose et al. 2000;
Takayama et al. 2000), endostatin (Chen et al. 2000; Feldman
et al. 2000) or a non-catalytic fragment of matrix metalloproteinase
2 (Pfeifer et al. 2000).
Alternative approaches are based on small molecules. Thus, the
VEGFR-2 inhibitor SU5416 has been shown to induce a signifi-
cant reduction of tumour vascular density in an experimental
murine brain tumour model (Vajkoczy et al. 2000), whereas the
fumagillin-derived TNP 470 or AGM 1470 (Ingber et al. 1990),
one of the first anti-angiogenic compounds described, has already
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entered clinical trials (Folkman, 1995; Kerbel, 1997; Belotti &
Castronovo, 1998).
Most receptors of angiogenic factors, such as VEGF or basic
fibroblast growth factor, as well as many components of recep-
tor-mediated downstream signalling, are tyrosine kinases
(Dionne et al. 1990; De Vries et al. 1992). Tyrosine kinase inhi-
bition is therefore favoured among anti-angiogenic strategies.
Genistein is a well-known tyrosine kinase inhibitor (Akiyama
et al. 1987) that has previously attracted interest as a novel angio-
genesis inhibitor (Fotsis, 1995; Fotsis et al. 1997). Genistein is an
isoflavone (5,7,40-trihydroxyisoflavone) that can be isolated from
tempeh, which is derived from soyabeans and is a popular food in
south-east Asian countries.
There is growing experimental evidence from in vitro and in
vivo studies showing that soyabean isoflavones, in particular gen-
istein, function as promising chemopreventive and/or therapeutic
agents, inhibiting carcinogenesis and the growth of different
human cancers such as breast, prostate and colon cancers (for
review, see Sarkar & Li, 2003).
Besides genistein, tempeh contains other isoflavones such as
daidzein (7,40-dihydroxyisoflavone) and 6,7,40-trihydroxyisofla-
vone (factor 2; Gyo¨rgy et al. 1964). Two novel isoflavones
(7,8,40-trihydroxyisoflavone (7,8,40-TriOH) and 5,7,30,40-tetrahy-
droxyisoflavone (orobol)) have been isolated from tempeh in
our laboratory in recent years (S Kiriakidis, M Kolvenbach, HC
Jha and H Egge, unpublished results). Both are biotransformation
products of genistein and daidzein and are produced during the
fermentation of soyabeans by enzymes from micro-organisms
(Klus & Barz, 1995).
In the present investigation, we tested the in vivo anti-angio-
genic properties of these novel compounds and of genistein, daid-
zein and factor 2 by evaluating their effects in the chicken
chorioallantoic membrane (CAM) assay. The CAM assay is fre-
quently used for screening purposes due to its economical price,
high capacity and ease of manipulation (Auerbach et al. 2003).
In order to understand their mechanism of action, we also tested
their effect on endothelial cell proliferation and on VEGF-induced
Ets 1 expression in cultured endothelial cells, since the Ets 1 tran-
scription factor has been intimately linked to the regulation of
new blood vessel formation under both physiological and pathologi-
cal conditions (Vandenbunder et al. 1989; Wernert et al. 1992; Iwa-
saka et al. 1996; Valter et al. 1999; Wernert et al. 1999).
Materials and methods
The isoflavones genistein, daidzein, factor 2, 7,8,40-TriOH and
orobol (for structures, see Fig. 1) were isolated from a methanolic
extract of tempeh. Their structures were verified by spectroscopic
methods (UV, MS and nuclear magnetic resonance) and by chroma-
tographic comparison (TLC–HPLC) with synthetic substances of
known structure. These substances were subsequently synthesized,
since the quantity of the isolated substances was not sufficient for
the present investigation.
Chemicals, growth factors and antibodies
Chemicals and organic solvents of analytical grade, silica gel 60
F254 HP TLC plates and CHOD-PAP reagents were obtained from
Merck (Darmstadt, Germany). Sephadexw LH 20 was from Phar-
macia (Uppsala, Sweden).
Recombinant human VEGF was obtained from TEBU (Frank-
furt, Germany). It was stored and used according to manufac-
turer’s recommendations.
For Ets 1 detection, a monoclonal mouse antibody (directed
against amino acids 122–288; Transduction Laboratories, Lex-
ington, KY, USA) (Fleischman et al. 1995) and a polyclonal
rabbit antibody (against amino acids 422–441;, Santa Cruz, CA
, USA) (Fisher et al. 1992) were used. The a-tubulin antibody
was obtained from Santa Cruz Biotechnology.
Isolation of isoflavones from tempeh
Fresh tempeh purchased from a local store (100 g wet weight) was
mixed with 300 ml methanol and minced using an Ultra-Turrax
homogenizer (Janke & Kunkel, Staufen, Germany) for 5 min. The
slurry was filtered through a Buchner filter and the residue treated
three times in the same way. Evaporation of the filtrates under
vacuum yielded 11·1 g crude tempeh extract. The extract was
defatted on a Sephadex LH 20 column (i.d. 20 mm, length
500 mm) using methanol as eluant. Fractions (3 ml) were collected
and 5ml aliquots were spotted onto a silica gel 60 F254 HP TLC plate
(Merck) followed by development in cyclohexane–dichloro-
methane–ethylformate–formic acid (35:30:30:5, by vol.). The
plates were examined under UV light (l 254 nm) and the isoflavone
spots detected by co-chromatography with authentic isoflavones.
After separation of the isoflavones, their structures were determined
by spectroscopic methods (UV, MS, nuclear magnetic resonance).
The isoflavones eluted from the column shortly after the lipids
(e.g. triacylglycerols, phospholipids, NEFA) were completely
removed from the column. All isoflavone-containing fractions
were pooled and the solvent was evaporated in vacuum (yield
230 mg).
The isoflavone fraction was examined with HPLC using a
Chromspher 5B column (3 £ 100 mm) and acetonitrile–0·1 M-
KH2PO4 (35:65, v/v) as eluant at 0·4 ml/min. Detection was at UV
260 nm with recording and integration using Eurochrom 2000 soft-
ware (Knauer, Berlin, Germany). Genistein and daidzein were pre-
sent at concentrations of 38 and 18 mg respectively; the
Fig. 1. Chemical structures of tempeh isoflavones. (A), 5,7,40-trihydroxyiso-
flavone (genistein); (B), 7,40-dihydroxyisoflavone (daidzein); (C), 6,7,40-trihy-
droxyisoflavone (factor 2); (D), 5,7,30,40-tetrahydroxyisoflavone (orobol); (E),
7,8,40-trihydroxyisoflavone.
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concentrations of the other thee isoflavones ranged between 10 and
5 mg/kg fresh tempeh.
Evaluation of the anti-angiogenic effect of different isoflavones in
the chicken chorioallantoic membrane assay
Fertilized chicken eggs were incubated for 2 d at 378C under a con-
stant relative humidity of 80 %. On day 2, eggs were treated with
ethanol (700 g/l). Albumin (3–5 ml) was then aspirated at the egg
poles under a laminar flow hood with a sterile needle in order to
allow detachment of the developing CAM from the eggshell.
Holes were sealed with BIOCLUSIVEe transparent dressing
(Johnson and Johnson, Arlington, TX, USA). Eggs were then incu-
bated in a horizontal position. On day 3 a square-shaped window
was cut in the shell using sterile scissors and forceps. This
window served as a portal of access for the CAM.
Application of isoflavones on the chorioallantoic membrane assay
by the platelet test
Isoflavones were dissolved in ethanol (800 ml/l) to a final concen-
tration of 50mM. The solution was applied on Thermanox plate-
lets (8 £ 8 mm; Nune, Wiesbaden, Germany), which were then
dried under a laminar flow hood. Thermanox platelets treated
only with ethanol (800 ml/l) served as negative controls.
Platelets with the isoflavone compounds or solution alone were
then laid upon the CAM and the eggshells were closed using BIO-
CLUSIVEe transparent dressing (Johnson and Johnson). Eggs
were returned to the incubator and the results evaluated on day
6 of development.
Computer-assisted densitometric evaluation of angiogenesis
Randomly selected regions were photographed (using a Wild
Microscope M420, magnification £ 100; Leitz, Oberkochen,
Germany) to show blood vessels beneath the platelets. Colour
slides were then recorded on a black and white charged-coupled
device camera (2720 £ 1769 pixel) and digitalized into grey-
scale 12 bit. Intensities of clearly visible blood vessel structures
varied between 409 and 2694 (range of grey value intensities
0–4096). Blood vessel surfaces were measured by determining
the surface of these grey values using the Image Pro Plus Software
(Media Cybernetics, Go¨ttingen, Germany).
Cell culture
Human umbilical vein endothelial cells were obtained from TEBU
and cultured in Medium 200 (TEBU) with low serum growth sup-
plement in humidified air with 5 % CO2 at 378C. After confluence,
cells were maintained in medium without low serum growth sup-
plement for 4 h and then stimulated (for 4 h) with VEGF (10 ng/
ml) with or without the different tempeh constituents (50mM).
Cells were then processed for protein extraction.
Protein extraction and Western blotting
Cells were lysed in 1 ml TRIzol Reagent (Life Technologies Inc.,
Carlsbad, CA, USA) and protein was isolated according to the man-
ufacturer’s instructions. Equal amounts of protein (20mg per
sample) were separated by SDS–PAGE (1:10, w/v) gel electro-
phoresis and transferred to a nitrocellulose membrane in buffer
containing 25 mM-Tris, 150 mM-glycine and methanol (200 ml/l)
at 250 mA for 1 h. Membranes were blocked by incubation for
1 h in blocking solution (10 ml/l) (90 ml Tris-buffered saline
(50 mM-Tris, pH 7·5, 150 mM-NaCl) and 10 ml blocking stock sol-
ution (100 ml/l; Boehringer Mannheim, Mannheim, Germany)).
Both anti-Ets 1 primary antibodies were diluted 1:1000 in the
blocking solution (5 ml/l) and incubated with the membranes over-
night at 48C. Detection was carried out with horseradish (Armoracia
rusticana) peroxidase-conjugated affinity-purified goat antibody
directed against mouse–rabbit IgG (dilution 1:6000 in blocking
solution (5 ml/l), 40 min). The reaction was visualized on photo-
graphic films by H2O2–luminol chemiluminescence detection
using a kit (Boehringer Mannheim). Membranes were striped and
re-probed with the anti a-tubulin antibody to show equal loading
of proteins.
Cell proliferation assay
Endothelial cells were seeded on twenty-four-well plates at 1·5
£ 104 cells per ml and in Medium 200 (TEBU) with low serum
growth supplement in humidified air with 5 % CO2 at 378C and
incubated overnight to reach optimal cell adhesion. After
adhesion, recombinant human VEGF (10 ng/ml) alone or
together with the tempeh isoflavones at concentrations of 6,
12, 25 or 50mM (from a stock solution in dimethylsulfoxide)
were added to the culture dishes. Dimethylsulfoxide was used
as a vehicle control. The isoflavones or dimethylsulfoxide only
were added 1 h before VEGF on the first day of treatment.
Cells were then incubated for another 3 d and were counted
with a haemocytometer after Trypan Blue staining for viability
testing.
Statistical analysis
All data presented are from a representative experiment and the
total number of experiments performed is indicated. Statistical
analyses on the computer-assisted densitometric evaluation of
angiogenesis were carried out using the ‘One sample – Student’s
t test’ and the Duncan’s test for multiple comparisons using SPSS
software (SPSS Inc., Chicago, IL, USA). Comparison between
different eggs within the single isoflavone groups and control
groups was performed using the ‘One sample – Student’s t
test’ considering the same variances. In addition, multiple com-
parisons between the different isoflavones were made by use of
Duncan’s testing using the SPSS software.
Results
Tempeh isoflavones inhibit angiogenesis in the chicken CAM. Den-
sitometric evaluation of blood vessel surfaces revealed in vivo anti-
angiogenic effects of all isoflavones examined. Results are given in
Fig. 2. Compared with negative controls that slightly inhibited in
vivo angiogenesis by 6·30 %, genistein reduced angiogenesis by
75·09 %, followed by orobol (67·96 %), factor 2 (56·77 %), daidzein
(48·98 %) and 7,8,40-TriOH (24·42 %) (Table 1). With the Duncan’s
test we found no significant differences between the average
reduction of blood vessels observed between genistein and orobol
(P¼0·323). In addition there was no significant difference found
between orobol and factor 2 (P¼0·217). Finally, there was no sig-
nificant difference between factor 2 and daidzein (P¼0·343).
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Inhibition of vascular endothelial growth factor-stimulated
endothelial cell proliferation by tempeh isoflavones
In order to analyse possible mechanisms by which tempeh isofla-
vones might inhibit angiogenesis in the CAM, we next assessed
their effects on VEGF-stimulated human umbilical vein endo-
thelial cell proliferation. As shown in Fig. 3, we found that gen-
istein and orobol exerted the strongest anti-proliferative effects,
with orobol showing the highest inhibition at lower concentration
(10mM). Strong effects were also found for the other compounds
at a concentration of 50mM.
Tempeh isoflavones inhibit vascular endothelial growth factor-
induced Ets 1 expression in cultured endothelial cells
We then wished to elucidate possible molecular mechanisms by
which tempeh isoflavones might inhibit angiogenesis. To this
end, we investigated their effects on VEGF-induced expression
of the Ets 1 transcription factor, which has been strongly related
to angiogenesis under both physiological and pathological
conditions.
By Western blot analysis we found a strong induction of both
the p51 and the p39 Ets 1 proteins 4 h after VEGF stimulation
of human umbilical vein endothelial cells. These two proteins
are the translation products of the full-length Ets 1 transcript
(p51) and a splice variant lacking exon VII (p39; Fisher et al.
1992). As shown in Fig. 4, VEGF-induced expression of p51
was inhibited by genistein and by orobol, whereas the other iso-
flavones (factor 2, daidzein and 7,8,40-TriOH) had no effect.
Expression of p39 was strongly reduced by all isoflavones.
Discussion
Angiogenesis associated with solid tumours is believed to pro-
mote the proliferation, invasion and metastasis of cancer cells.
Indeed, multiple genes, including VEGF, involved in angiogen-
Fig. 2. Examples of inhibitory effects of different isoflavones on in vivo angiogenesis in the chicken chorioallantoic membrane assay. (A), daidzein; (B), genistein;
(C), factor 2; (D), orobol; (E), 7,8,40-trihydroxyflavone. Seven to ten eggs per isoflavone (one platelet per egg) were used to determine anti-angiogenic effects. Six
to ten randomly selected regions were photographed (Wild Microscope M420, magnification £ 100; ) to show blood vessels beneath the platelets and in a
neighbouring control (C) area without platelets. Platelets without isoflavones served as a negative control. Chorioallantoic blood vessels are visible beneath the
transparent platelets. Note in control (C) the presence of an increased number of blood vessels. Conversely, in the region treated with the effective isoflavones
genistein and orobol, only a very few new blood vessels can be seen. For details of procedures, see p. 319 and for details of the chemical structures of the isofla-
vones, see Fig. 1.
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esis have also been implicated in cancer progression and
metastasis. Thus, angiogenesis blockade is currently emerging
as a novel approach of great potential for cancer treatment,
and continuous efforts are made to develop new anti-angiogenic
strategies.
Several approaches are based on small molecules such as the
VEGFR-2 inhibitor SU5416, which has been shown to induce a
significant reduction of tumour vascular density in an experimen-
tal murine brain tumour model (Vajkoczy et al. 2000). One of the
first anti-angiogenic compounds, the fumagillin-derived TNP 470
or AGM 1470 (Ingber et al. 1990), has already entered clinical
trials (Folkman, 1995; Kerbel, 1997; Belotti & Castronovo, 1998).
The isoflavone genistein, a major ingredient of soyabean, has
also been found to inhibit angiogenesis in vitro and in vivo and
tumour cell proliferation and tumour growth in vivo. In addition,
soyabean isoflavones have been identified as dietary components
that have an important role in reducing the incidence of different
human cancers, such as those of the breast and prostate (for
review, see Sarkar & Li, 2003).
In the present study, we have described the isolation of novel
isoflavones from tempeh, a fermented soyabean product and a
very popular food in south-east Asian countries. Using biological
tests we found that the novel isoflavones exhibited anti-angiogenic
effects in vivo in the chicken CAM assay and inhibited VEGF-
induced endothelial cell proliferation in vitro in a dose-dependent
manner. Although the relative concentration of orobol in tempeh
was lower in comparison with the concentration of genistein, we
found that both isoflavones had similar anti-angiogenetic potency.
It should be noted that in VEGF-stimulated endothelial cells,
orobol had a stronger anti-proliferative effect than genistein at
low concentrations (,20mM).
In order to identify possible molecular mechanisms by which iso-
flavones might exert their anti-angiogenic effect, we investigated
their ability to inhibit VEGF-induced expression of the Ets 1 tran-
scription factor, which has been intimately linked to the regulation
of angiogenesis in endothelial cells. Previously, we have shown that
antisense oligodesoxynucleotide blockade of Ets 1 inhibits angio-
genesis in the chicken CAM assay (Wernert et al. 1999) and that
the anti-angiogenic compound fumagillin strongly decreases
VEGF-induced Ets 1 expression in cultured endothelial cells (Wer-
nert et al. 1999). In the present study, we used both a monoclonal
mouse antibody, which recognizes p51 (the full-length isoform of
Ets1) and a polyclonal rabbit antibody, which can also recognize
products of alternatively spliced mRNA products such as p39
(p39 lacks exon VII) (Jorcyk et al. 1991; Kilpatrick et al. 1999).
We found that several isoflavones inhibited Ets 1 expression,
which suggests that Ets 1 inhibition might be one of the molecular
mechanisms underlying anti-angiogenesis in these settings. Inhi-
bition involved p51 Ets 1 and p39 Ets 1; the latter is translated
from a splice variant lacking exon VII. This exon encodes part of
the DNA-binding domain of Ets 1, other parts being encoded by
exons VIII and IX (Jorcyk et al. 1991). Whether p39 displays
DNA-binding properties other than p51 Ets 1 remains to be deter-
mined. In colon carcinoma cells p39 Ets 1 has been shown to
Table 1. Inhibitory effects of different isoflavones on angiogenesis in the chicken chorioallantoic membrane assay: comparison of reduction of blood vessel sur-
faces before and after normalization*
(Mean values and standard deviations)
Control
Isoflavone test groups (plus platelets)†
Genistein Orobol Factor 2 Daidzein 7,8,40-TriOH
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Reduction in blood
vessel surface (%)
6·35 3·16 81·44 11·94 73·31 18·33 63·12 25·79 55·33 17·77 30·77 14·41
t value 5·64 21·57 12·00 8·82 9·34 5·64
Statistical significance
of effect (P value)






0 75·09 3·94 67·96 6·21 56·77 7·24 48·98 6·03 24·42 5·22
7,8,40-TriOH, 7,8,40-trihydroxyisoflavone.
* For details of procedures, see p. 319, and for details of chemical structures of isoflavones, see Table 1.
† Test group sizes (number of eggs): control 8, genistein 10, orbol 9, factor 2 13, daidzein 9, 7,8,40-TriOH 7.
Fig. 3. Effect of increasing concentrations of tempeh isoflavones on the pro-
liferation of human umbilical vein endothelial cells. Cells were seeded at a
density of 1·5 £ 104 cells per well in twenty-four-well plates. After 24 h cells
were pre incubated with the tempeh isoflavones genistein (B), daidzein (O),
factor 2 (A), orobol (P), 7,8,40-trihydroxyflavone (W) at concentrations of
0–50mM or with vehicle (dimethylsulfoxide) for 1 h. Cells were then
stimulated with 10 ng vascular endothelial growth factor/ml cultured for a
further 3 d and then counted using a haemocytometer. For details of
procedures, see p. 319 and for details of the chemical structures of the isofla-
vones, see Fig. 1. Values are expressed as a percentage of controls, i.e.
dimethylsulfoxide treated–vascular endothelial growth factor stimulated cells
only (usually in the range of 80 000 cells per well). Values are means for tri-
plicate wells with standard errors shown by vertical bars. A representative of
six independent experiments is shown.
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rescue Fas-induced apoptosis (Huang et al. 1997; Li et al. 1999;
Shiose et al. 2000).
The finding that the two splice variants of Ets 1 are differen-
tially influenced by the isoflavones could be a hint of different
mechanisms of inhibition that they cause. We found that factor
2, 7,8,40-TriOH and daidzein only reduced the expression of the
p39 Ets 1 splice variant. Although this could be achieved by a
general inhibitory effect on the spliceosome, this is unlikely, as
both genistein and orobol were able to reduce the Ets 1 expression
rate of p39 as well as of p51. Therefore, it appears that genistein
and orobol are specific inhibitors of the VEGF-induced expression
of Ets 1. This finding fits well with the observation that genistein
and orobol are the most potent inhibitors of angiogenesis in the
CAM assay and that they exert the strongest anti-proliferative
effects in the cell proliferation assay.
Comparison of the chemical structure of the different isofla-
vones suggests potential structure–activity relationships (Fig. 1).
The 40-OH group present in ring B of genistein (and all other
compounds) has been previously shown to be essential for the
tyrosine kinase inhibitory activity and the anti-tumour properties
of genistein (Fotsis et al. 1997). Moreover, isoflavones possess
a polyphenol structure, and it is known that o-dihydroxy groups
in phenols enable them to function as strong antioxidants, captur-
ing free oxygen radicals implicated in signal transduction path-
ways, which leads to cell proliferation (Fotsis et al. 1997).
o-Dihydroxy groups are present at 30,40 of ring B in orobol,
which thus possesses both elements supposed to be necessary
for anti-proliferative effects (a 40-OH group and an o-dihy-
droxy-group).
By evaluating the antioxidant activity of the isoflavones using
the method of superoxide dismutase-inhibitable O2
2 production
by xanthine–xanthine oxidase, we found that the antioxidant
activity of orobol was greater than that of genistein. Furthermore,
a mixture of the isoflavones showed much higher inhibition of
O2
2 production compared with individual isoflavones, probably
due to a synergistic effect (S Kiriakidis, M Kolvenbach, HC Jha
and H Egge, unpublished results).
It has been reported recently that reactive oxygen species, which
induce migration and proliferation of cultured endothelial cells,
also induce Ets 1 expression (Yasuda et al. 1999). Inhibition of
both Ets 1 expression and endothelial cell proliferation by isofla-
vones could therefore be due to their tyrosine kinase inhibitory
as well as their antioxidative effects. There is no o-dihydroxy
group in daidzein, which is also the least hydroxylated of the inves-
tigated compounds. This may explain its low activity in some of
our present experiments.
Although genistein is likely to be the major active component in
tempeh, and the majority of the studies so far refer to genistein and
daidzein as the sole soyabean isoflavones, our present results show,
for the first time to our knowledge, that other active isoflavones are
also present in tempeh. These isoflavones might become additional
low molecular mass compounds that have potential for the
inhibition of angiogenesis and angiogenesis-related diseases.
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